Waters Corporation announced its financial results for the fourth quarter and full-year 2024 on February 12, 2025. For Q4 2024, sales reached $873 million, a 6% increase as reported, with non-GAAP diluted EPS growing 13% to $4.10, surpassing analyst estimates.
Full-year 2024 sales were $2,958 million, flat as reported, while non-GAAP EPS increased 1% to $11.86. The fourth quarter saw strong performance in the pharmaceutical market, with sales up 8% reported and 10% in constant currency, and instrument system sales increasing 6% reported and 8% in constant currency.
Waters provided full-year 2025 constant currency sales growth guidance in the range of +4.5% to +7.0%, and non-GAAP EPS guidance of $12.70 to $13.00. However, the company's first-quarter 2025 non-GAAP EPS guidance of $2.17 to $2.25 fell below analysts' average estimate of $2.42 per share, primarily due to an estimated 7% headwind from unfavorable foreign exchange.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.